Kelun Pharmaceutical: Shunitinib malate capsules obtained the drug registration certificate, which will further enrich the company's product pipeline in the field of oncology

Release Easy March 24 - Kelun Pharmaceutical (002422) announced that the company's subsidiary Hunan Kelun Pharmaceutical Co., Ltd. recently obtained the "Drug Registration Certificate" of the chemical drug "Sunitinib malate capsules" approved and issued by the State Drug Administration. At present, the company has three anti-tumor drugs of gefitinib tablets, zoledronic acid injection (4mg/100ml), and paclitaxel for injection (albumin-binding type) approved for listing, and has formed a preliminary product cluster in the field of tumors. The approval of the company's sunitinib malate capsules and the approval of the subsequent series of varieties will further enrich the company's product pipeline in the field of oncology.

This article originated from Easy Publishing